KaloBios Provides Update on KB001-A Partnership and Clinical Status
PR Newswire - Mon Jul 28, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on the status of the KB001-A development program, including an update on its KB001-A collaboration with Sanofi Pasteur.
Cutera, Inc. (CUTR) in Focus: Stock Adds 7.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:11AM CDT
Cutera, Inc. (CUTR) was a big mover last session, as the company saw its shares rise over 7% on the day.
5 Stocks Under $10 Setting Up to Soar
at The Street - Thu Jun 26, 12:56PM CDT
These under-$10 stocks look poised to break out and trade higher from current levels.
3 Health Care Stocks Under $10 to Trade for Breakouts
at The Street - Wed Jun 25, 7:34AM CDT
These under-$10 health care stocks are within range of triggering breakout trades.
Akorn (AKRX) in Focus: Stock Moves 5.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:18AM CDT
Akorn, Inc. (AKRX) was a big mover last session, as the company saw its shares rise by almost 6% on the day.
Aquinox Pharmaceuticals (AQXP) in Focus: Stock Plunges 15.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:00AM CDT
Aquinox Pharmaceuticals has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the last day
Acasti Pharma Inc (ACST) Jumps: Stock Rises 7.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:30AM CDT
Acasti Pharma Inc. (ACST) was a big mover last session, as its shares rose over 7% on the day.
Will KaloBios (KBIO) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 9:22AM CDT
Will KaloBios (KBIO) Continue to Surge Higher?
KaloBios to Present at 9th Annual JMP Securities Healthcare Conference
PR Newswire - Wed Jun 11, 1:00PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following investor conference:
KaloBios (KBIO) Worth Watching: Stock Jumps 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 8:25AM CDT
KaloBios (KBIO) was a big mover last session, as the company saw its shares rise nearly 13% on the day.
Weakness Seen in Relypsa (RLYP): Stock Falls 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 7:58AM CDT
Relypsa (RLYP) fell over 7% in the last trading session amid huge volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
Teva to Buy Labrys Biologics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 04, 11:10AM CDT
Teva Pharmaceutical Industries Ltd. (TEVA) will acquire development-stage biotech company, Labrys Biologics, Inc. for an upfront payment of $200 million.
KaloBios Pharmaceuticals (KBIO) Worth Watching: Stock Up 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 29, 8:25AM CDT
KaloBios Pharmaceuticals (KBIO) was a big mover last session, with shares rising over 5% on the day.
3 Stocks Under $10 Moving Higher
at The Street - Fri May 23, 6:35AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
KaloBios to Present at Jefferies 2014 Global Healthcare and BBC Boston CEO Conferences
PR Newswire - Wed May 21, 11:28AM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following investor conferences:
Where are They Now? Biotech IPO Class of 2013, March Edition
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
This year you can't squeeze a pipette without hitting another biotech offering. The red-hot sector has seen more than 25 IPOs so far this year. Many are doubling and tripling in price in their first days of trading. In a frenzied market like this...
How KaloBios (KBIO) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:33AM CDT
KaloBios is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 9 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
KaloBios Announces Fiscal Year 2013 Financial Results
PR Newswire - Thu Mar 13, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on corporate accomplishments in fiscal 2013 and key milestones for 2014 as well as announcing financial results for fiscal year 2013.
KaloBios Announces Upcoming Participation at ROTH and BioCentury's Future Leaders in the Biotech Industry Conferences
PR Newswire - Mon Mar 10, 3:01PM CDT
KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will be presenting at the following upcoming investor conferences:
Envestnet President Bill Crager To Chair Panel At ABA Wealth Management And Trust Conference
PR Newswire - Wed Feb 26, 7:45AM CST
Envestnet, Inc. (NYSE: ENV), a leading provider of integrated wealth management technology and services to investment advisors and wealth managers, announces that President Bill Crager will moderate a panel discussion at the American Bankers Association (ABA) Wealth Management and Trust Conference, which will take place from February 26-28, 2014 at the Hilton San Diego Bayfront Hotel.